Cargando…

QiShenYiQi Inhibits Tissue Plasminogen Activator–Induced Brain Edema and Hemorrhage after Ischemic Stroke in Mice

Background: Thrombolysis with tissue plasminogen activator (tPA) remains the only approved drug therapy for acute ischemic stroke. However, delayed tPA treatment is associated with an increased risk of brain hemorrhage. In this study, we assessed whether QiShenYiQi (QSYQ), a compound Chinese medicin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Yang, Li, Quan, Pan, Chun-Shui, Yan, Li, Sun, Kai, Wang, Xiao-Yi, Yao, Shu-Qi, Fan, Jing-Yu, Han, Jing-Yan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790519/ https://www.ncbi.nlm.nih.gov/pubmed/35095486 http://dx.doi.org/10.3389/fphar.2021.759027

Ejemplares similares

Galectin-3 Mediated Inflammatory Response Contributes to Neurological Recovery by QiShenYiQi in Subacute Stroke Model
por: Wang, Yule, et al.
Publicado: (2021)

The Contribution of Different Components in QiShenYiQi Pills® to Its Potential to Modulate Energy Metabolism in Protection of Ischemic Myocardial Injury
por: Cui, Yuan-Chen, et al.
Publicado: (2018)

QiShenYiQi Attenuates Renal Interstitial Fibrosis by Blocking the Activation of β-Catenin
por: Zhou, Zhanmei, et al.
Publicado: (2016)

Effect and Mechanism of QiShenYiQi Pill on Experimental Autoimmune Myocarditis Rats
por: Lv, Shichao, et al.
Publicado: (2016)

QiShenYiQi pill improves the reparative myocardial fibrosis by regulating autophagy
por: Lv, Shichao, et al.
Publicado: (2020)

QiShenYiQi Pill Improves Myocardial Hypertrophy Caused by Pressure Overload in Rats
por: Lv, Shichao, et al.
Publicado: (2021)

Integrated network pharmacology and metabolomics to reveal the mechanism of QiShenYiQi Dripping Pills against cardiac structural and functional abnormalities
por: Zhang, Jun, et al.
Publicado: (2022)

QiShenYiQi pill for myocardial collagen metabolism and apoptosis in rats of autoimmune cardiomyopathy
por: Lv, Shichao, et al.
Publicado: (2022)

Cardioprotection against ischemia/reperfusion injury by QiShenYiQi Pill(®) via ameliorate of multiple mitochondrial dysfunctions
por: Chen, Jing Rui, et al.
Publicado: (2015)

Corrigendum: Integrated network pharmacology and metabolomics to reveal the mechanism of QiShenYiQi Dripping Pills against cardiac structural and functional abnormalities
por: Zhang, Jun, et al.
Publicado: (2022)

Effect of QiShenYiQi Pill on Myocardial Collagen Metabolism in Rats with Partial Abdominal Aortic Coarctation
por: Lv, Shichao, et al.
Publicado: (2015)

QiShenYiQi Pill Ameliorates Cardiac Fibrosis After Pressure Overload-Induced Cardiac Hypertrophy by Regulating FHL2 and the Macrophage RP S19/TGF-β1 Signaling Pathway
por: Anwaier, Gulinigaer, et al.
Publicado: (2022)

QiShenYiQi Pills, a Compound Chinese Medicine, Prevented Cisplatin Induced Acute Kidney Injury via Regulating Mitochondrial Function
por: Zhou, Li, et al.
Publicado: (2017)

QiShenYiQi Pills, a Compound Chinese Medicine, Ameliorates Doxorubicin-Induced Myocardial Structure Damage and Cardiac Dysfunction in Rats
por: Tang, Dong-Xin, et al.
Publicado: (2013)

A critical courier role of volatile oils from Dalbergia odorifera for cardiac protection in vivo by QiShenYiQi
por: Yu, Jiahui, et al.
Publicado: (2017)

Cardioprotective Effects of QiShenYiQi Dripping Pills on Transverse Aortic Constriction-Induced Heart Failure in Mice
por: Ruan, Guoran, et al.
Publicado: (2018)

QiShenYiQi pill attenuates atherosclerosis by promoting regulatory T cells, inhibiting T helper 17 cells and accelerating cholesterol excretion
por: Peng, Li, et al.
Publicado: (2017)

QiShenYiQi Pills Attenuates Ischemia/Reperfusion-Induced Cardiac Microvascular Hyperpermeability Implicating Src/Caveolin-1 and RhoA/ROCK/MLC Signaling
por: Pan, Chun-Shui, et al.
Publicado: (2021)

QiShenYiQi pills, a Chinese patent medicine, increase bioavailability of atorvastatin by inhibiting Mrp2 expression in rats
por: Ding, Congyang, et al.
Publicado: (2022)

QiShenYiQi Pills, a compound in Chinese medicine, protects against pressure overload-induced cardiac hypertrophy through a multi-component and multi-target mode
por: Chen, Yuan-Yuan, et al.
Publicado: (2015)

Identifying roles of “Jun-Chen-Zuo-Shi” component herbs of QiShenYiQi formula in treating acute myocardial ischemia by network pharmacology
por: Wu, Leihong, et al.
Publicado: (2014)

QiShenYiQi pill activates autophagy to attenuate reactive myocardial fibrosis via the PI3K/AKT/mTOR pathway
por: Lv, Shichao, et al.
Publicado: (2021)

A Network Pharmacology Study of Chinese Medicine QiShenYiQi to Reveal Its Underlying Multi-Compound, Multi-Target, Multi-Pathway Mode of Action
por: Li, Xiang, et al.
Publicado: (2014)

Qi-Shen-Yi-Qi Dripping Pills for the Secondary Prevention of Myocardial Infarction: A Randomised Clinical Trial
por: Shang, Hongcai, et al.
Publicado: (2013)

Qi-Shen-Yi-Qi Dripping Pills Promote Angiogenesis of Ischemic Cardiac Microvascular Endothelial Cells by Regulating MicroRNA-223-3p Expression
por: Dai, Guo-Hua, et al.
Publicado: (2016)

ShenQiWan ameliorates renal injury in type 2 diabetic mice by modulating mitochondrial fusion and endoplasmic reticulum stress
por: Xiong, Wei, et al.
Publicado: (2023)

Investigation of Invigorating Qi and Activating Blood Circulation Prescriptions in Treating Qi Deficiency and Blood Stasis Syndrome of Ischemic Stroke Patients: Study Protocol for a Randomized Controlled Trial
por: Wang, Yu, et al.
Publicado: (2020)

Exploring the Mechanisms of Modified Bu-Shen-Yi-Qi Decoction for COPD-Related Osteoporosis Therapy via Transcriptomics and Network Pharmacology Approach
por: Zhong, Yuanyuan, et al.
Publicado: (2023)

Qing-Re-Xiao-Zheng-Yi-Qi formula relieves kidney damage and activates mitophagy in diabetic kidney disease
por: Wu, Qiaoru, et al.
Publicado: (2022)

BuShenYiQi Granule Inhibits Atopic Dermatitis via Improving Central and Skin Hypothalamic -Pituitary -Adrenal Axis Function
por: Kong, Lingwen, et al.
Publicado: (2015)

The chemical components, action mechanisms, and clinical evidences of YiQiFuMai injection in the treatment of heart failure
por: Lv, Shichao, et al.
Publicado: (2022)

Correction: BuShenYiQi Granule Inhibits Atopic Dermatitis via Improving Central and Skin Hypothalamic -Pituitary -Adrenal Axis Function
por: Kong, Lingwen, et al.
Publicado: (2015)

Target Identification of Active Constituents of Shen Qi Wan to Treat Kidney Yang Deficiency Using Computational Target Fishing and Network Pharmacology
por: Zhang, Jie Ying, et al.
Publicado: (2019)

Exploring the comorbidity mechanisms between asthma and idiopathic pulmonary fibrosis and the pharmacological mechanisms of Bu-Shen-Yi-Qi decoction therapy via network pharmacology
por: Zhong, Yuanyuan, et al.
Publicado: (2022)

Identification of the Active Constituents and Significant Pathways of Shen-qi-Yi-zhu Decoction on Antigastric Cancer: A Network Pharmacology Research and Experimental Validation
por: Zeng, Shuhong, et al.
Publicado: (2021)

Academician Qi-Yi Xing (Chi-Yi Hsing): pioneer organic chemist of synthetic insulin
por: Qiu, Ming-Hua
Publicado: (2021)

The Protective Effect of Shen Qi Wan on Adenine-Induced Podocyte Injury
por: Lin, Yiyou, et al.
Publicado: (2020)

The Chinese Herb Yi-Qi-Huo-Xue Protects Cardiomyocyte Function in Diabetic Cardiomyopathy
por: Wang, Xiangsheng, et al.
Publicado: (2018)

QiHuangYiShen Granules Modulate the Expression of LncRNA MALAT1 and Attenuate Epithelial-Mesenchymal Transition in Kidney of Diabetic Nephropathy Rats
por: Yuan, Li-sha, et al.
Publicado: (2023)

A Randomized Controlled Study of the Yi Qi Gu Biao Pill in the Treatment of Frequent Exacerbator Phenotype in Chronic Obstructive Pulmonary Disease (Lung and Spleen Qi Deficiency Syndrome)
por: Zhen, Gao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n0dk49blkg67jb1nm4lm5qdh9b